BR112013009932A2 - análogos do peptídeo insulinotrópico dependente de glicose - Google Patents

análogos do peptídeo insulinotrópico dependente de glicose

Info

Publication number
BR112013009932A2
BR112013009932A2 BR112013009932A BR112013009932A BR112013009932A2 BR 112013009932 A2 BR112013009932 A2 BR 112013009932A2 BR 112013009932 A BR112013009932 A BR 112013009932A BR 112013009932 A BR112013009932 A BR 112013009932A BR 112013009932 A2 BR112013009932 A2 BR 112013009932A2
Authority
BR
Brazil
Prior art keywords
glucose
dependent insulinotropic
peptide analogues
insulinotropic peptide
compounds
Prior art date
Application number
BR112013009932A
Other languages
English (en)
Inventor
George Ehrlich
Jefferson Wright Tilley
Joseph Swistok
Wajiha Khan
Waleed Danho
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013009932A2 publication Critical patent/BR112013009932A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

análogos do peptídeo insulinotrópico dependente de glicose. a presente invenção fornece compostos que são análogos do popipetídeo insulinotrópico dependente de glicose (gip) e sais farmaceuticamente aceitáveis de tais compostos. estes compostos tem atividade como agonistas do receptor de gip.
BR112013009932A 2010-10-25 2011-10-21 análogos do peptídeo insulinotrópico dependente de glicose BR112013009932A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40618610P 2010-10-25 2010-10-25
PCT/EP2011/068385 WO2012055770A1 (en) 2010-10-25 2011-10-21 Glucose-dependent insulinotropic peptide analogs

Publications (1)

Publication Number Publication Date
BR112013009932A2 true BR112013009932A2 (pt) 2016-08-02

Family

ID=44860359

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009932A BR112013009932A2 (pt) 2010-10-25 2011-10-21 análogos do peptídeo insulinotrópico dependente de glicose

Country Status (12)

Country Link
US (1) US9023986B2 (pt)
EP (1) EP2632945A1 (pt)
JP (1) JP2013542211A (pt)
KR (1) KR20130127985A (pt)
CN (1) CN103180338A (pt)
AR (1) AR083528A1 (pt)
BR (1) BR112013009932A2 (pt)
CA (1) CA2815140A1 (pt)
MX (1) MX2013004350A (pt)
RU (1) RU2013120135A (pt)
TW (1) TW201305197A (pt)
WO (1) WO2012055770A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3189072T3 (pl) 2014-09-05 2019-04-30 Univ Copenhagen Analogi peptydowe gip
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
CN110691788B (zh) 2017-05-31 2024-05-31 哥本哈根大学 长效gip肽类似物
MA52483A (fr) 2018-05-04 2021-03-10 Novo Nordisk As Dérivés de gip et leurs utilisations
US20220016215A1 (en) 2018-09-24 2022-01-20 Takeda Phaarmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
CN113366014A (zh) 2018-12-03 2021-09-07 安泰博医药 经修饰的gip肽类似物
CA3174635A1 (en) 2020-03-06 2021-09-10 Sanofi Peptides as selective gip receptor agonists
AU2021250319A1 (en) 2020-03-31 2022-12-01 Antaros Medical Ab Selective GIP receptor agonists comprising a chelating moiety for imaging and therapy purposes
AU2022339059A1 (en) 2021-09-06 2024-05-02 Sanofi New peptides as potent and selective gip receptor agonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
GB0404124D0 (en) * 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
CA2367856C (en) 1999-03-29 2013-10-15 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
CA2489323A1 (en) 2002-06-15 2003-12-24 Enteromed, Inc. Treatment of non-alcoholic fatty liver disease
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
WO2007028633A2 (en) 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
WO2007028632A2 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
EP2057188B1 (en) 2006-08-17 2013-07-31 Amylin Pharmaceuticals, LLC Dpp-iv resistant gip hybrid polypeptides with selectable properties
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
GB0717388D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CL2009001425A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
GB0814068D0 (en) 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
CN103641906A (zh) 2008-08-07 2014-03-19 益普生制药股份有限公司 葡萄糖依赖性促胰岛素多肽类似物
JP2011530506A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドの切り詰められたアナログ
WO2010016944A2 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
CN104829706A (zh) 2008-08-07 2015-08-12 益普生制药股份有限公司 糖依赖性胰岛素释放肽的类似物
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20110171312A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs

Also Published As

Publication number Publication date
US9023986B2 (en) 2015-05-05
EP2632945A1 (en) 2013-09-04
RU2013120135A (ru) 2014-12-10
CN103180338A (zh) 2013-06-26
TW201305197A (zh) 2013-02-01
AR083528A1 (es) 2013-03-06
WO2012055770A1 (en) 2012-05-03
CA2815140A1 (en) 2012-05-03
JP2013542211A (ja) 2013-11-21
KR20130127985A (ko) 2013-11-25
MX2013004350A (es) 2013-06-07
US20120101037A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
BR112013009932A2 (pt) análogos do peptídeo insulinotrópico dependente de glicose
ECSP12012181A (es) Nuevos péptidos y métodos para su preparación y uso
HK1217951A1 (zh) 抗纖維化劑的稠環類似物
EA201200239A1 (ru) Бициклические арильные аналоги сфингозин 1-фосфата
PH12014502452A1 (en) Gip-glp-1 dual agonist compounds and methods
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
IL216468A0 (en) Compositions, methods & systems for respiratory respiratory delivery of two or more active agents
MY163083A (en) Solid forms of a pharmaceutically active substance
HK1221653A1 (zh) 用於呼吸遞送三種或更多種活性劑的組合物、方法和系統
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
IN2014MN01433A (pt)
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
EA201270216A1 (ru) Фармацевтический состав
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
MX2015005735A (es) Moduladores de dihidropirazol de receptor acoplado a la proteona g (gpr40).
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
AR087501A1 (es) Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1
BR112014008555A2 (pt) r(+)-n-formil-propargil-aminoindano
MX362879B (es) Usos novedosos.
UY34629A (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubicuitina
BR112013018290A2 (pt) antagonistas de receptor 2 ativado por protease (par2)
IN2014DN07996A (pt)
BR112013027222A2 (pt) composição de liberação prolongada que contém peptídeos como ingrediente ativo
BR112013012503A2 (pt) análogos de bombesina marcados com 177 lutécio para radioterapia
BR112015005738A2 (pt) formulações orais de angiotensina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI